Alnylam's Q2 2025 earnings call highlights strong revenue growth driven by successful product launches and increased guidance, despite some decreased collaboration revenue and increased operating expenses. The overall sentiment is positive due to the significant achievements and strong financial performance.

Company Guidance -

Q3 2025

During the Alnylam Q2 2025 earnings call, the company provided robust guidance based on strong performance metrics. Alnylam reported total net product revenues of $672 million, marking a 64% increase year-over-year, driven by 77% growth in the TTR franchise, primarily due to the AMVUTTRA ATTR-CM launch. The company observed a 51% increase in global TTR product revenues compared to Q1 2025, with approximately 1,400 cardiomyopathy patients receiving AMVUTTRA, contributing about $150 million in revenue. As a result, Alnylam increased its 2025 total net product revenue guidance from $2.05-$2.25 billion to $2.65-$2.8 billion, representing a $575 million increase or 27% at the midpoint. The updated guidance assumes significant contributions from international markets in the second half of the year and reflects expectations for sustained growth across the portfolio, underscored by the successful early uptake of AMVUTTRA in both first-line and stabilizer-progressor patient populations.

Record-Breaking TTR Franchise Revenue

TTR franchise revenues reached $544 million, marking a 77% year-over-year growth, largely driven by the AMVUTTRA CM launch.

Strong Overall Financial Performance

Alnylam reported its strongest quarter to date with $672 million in total net product revenues, representing a 64% growth year-over-year.

Increased Revenue Guidance for 2025

Total net product revenues guidance for 2025 increased from $2.05 billion-$2.25 billion to a revised range of $2.65 billion-$2.8 billion, a 27% increase at the midpoint.

Successful AMVUTTRA Launch

Approximately 1,400 cardiomyopathy patients were receiving AMVUTTRA by June 30, contributing an estimated $150 million in revenue.

FDA Fast Track Designation for Nucresiran

Nucresiran received Fast Track Designation from the FDA for ATTR-CM, promising a more streamlined review process.

International Expansion

Launched AMVUTTRA in Germany and Japan, with further global expansion underway in Europe, Japan, and Brazil.

Alnylam Pharma (ALNY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ALNY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 23, 2025	2025 (Q3)	0.23 / -	-0.87	―	―	―
Jul 31, 2025	2025 (Q2)	-0.54 / -0.51	-0.13	-292.31% (-0.38)
May 01, 2025	2025 (Q1)	-0.89 / -0.44	-0.52	15.38% (+0.08)
Feb 13, 2025	2024 (Q4)	-0.59 / -0.65	-1.1	40.91% (+0.45)
Oct 31, 2024	2024 (Q3)	-0.92 / -0.87	1.15	-175.65% (-2.02)
Aug 01, 2024	2024 (Q2)	-1.07 / -0.13	-2.21	94.12% (+2.08)
May 02, 2024	2024 (Q1)	-1.12 / -0.52	-1.4	62.86% (+0.88)
Feb 15, 2024	2023 (Q4)	-1.19 / -1.10	-1.68	34.52% (+0.58)
Nov 02, 2023	2023 (Q3)	-1.45 / 1.15	-3.32	134.64% (+4.47)
Aug 03, 2023	2023 (Q2)	-1.51 / -2.21	-2.29	3.49% (+0.08)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ALNY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$339.80	$392.24	+15.43%
May 01, 2025	$263.24	$255.13	-3.08%
Feb 13, 2025	$265.96	$264.89	-0.40%
Oct 31, 2024	$281.49	$266.59	-5.29%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Alnylam Pharmaceuticals (ALNY) report earnings?

Alnylam Pharmaceuticals (ALNY) is schdueled to report earning on Oct 23, 2025, Before Open (Confirmed).

What is Alnylam Pharmaceuticals (ALNY) earnings time?

Alnylam Pharmaceuticals (ALNY) earnings time is at Oct 23, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ALNY EPS forecast?

ALNY EPS forecast for the fiscal quarter 2025 (Q3) is 0.23.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing